Transporter hypothesis of drug-resistant epilepsy: Challenges for pharmacogenetic approaches

Pharmacogenomics

Volumn 11, Issue 10, 2010, Pages 1427-1438

  Potschka, Heidrun ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

ABC transporter; antiepileptic drug; drug resistance; epilepsy; P glycoprotein; polymorphism

Indexed keywords

ANTICONVULSIVE AGENT; CYCLOOXYGENASE 2; ETIRACETAM; GLYCOPROTEIN P; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VERAPAMIL;

BLOOD BRAIN BARRIER; DRUG EFFICACY; DRUG TRANSPORT; EPILEPSY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PHARMACOGENOMICS; PROTEIN TRANSPORT; REVIEW; SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; EPILEPSY; HUMANS; MEMBRANE TRANSPORT PROTEINS;

EID: 78149319882     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.126     Document Type: Review

References (79)

1. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ: Predictors of pharmacoresistant epilepsy. Epilepsy Res. 75(2-3), 192-196 (2007).
2. Kwan P, Sperling MR: Refractory seizures: try additional antiepileptic drugs (after two have failed) or go directly to early surgery evaluation? Epilepsia 50(Suppl. 8), 57-62 (2009).
3. Kwan P, Arzimanoglou A, Berg AT et al.: Defnition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51(6), 1069-1077 (2009).
4. Loscher W, Potschka H: Drug resistance in brain diseases and the role of drug effux transporters. Nat. Rev. Neurosci. 6(8), 591-602 (2005).
5. Remy S, Beck H: Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129(Pt 1), 18-35 (2006).
6. Marchi N, Betto G, Fazio V et al.: Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema. Epilepsia 50(4), 664-677 (2009).
7. Rogawski MA, Johnson MR: Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr. 8(5), 127-130 (2008).
8. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C: MRD1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36(1), 1-6 (1995).
9. Loscher W, Potschka H: Role of drug effux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76(1), 22-76 (2005). (Pubitemid 41033402)
10. van Vliet E, Aronica E, Redeker S et al.: Selective and persistent upregulation of MDR1B mRNA and p-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res. 60(2-3), 203-213 (2004).
11. Volk HA, Potschka H, Loscher W: Increased expression of the multidrug transporter p-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res. 58(1), 67-79 (2004).
12. Volk H, Potschka H, Loscher W: Immunohistochemical localization of p-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fxation and staining variables. J. Histochem. Cytochem. 53(4), 517-531 (2005).
13. Seegers U, Potschka H, Loscher W: Transient increase of p-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy Epilepsy Res. 51(3), 257-268 (2002).
14. Hoffmann K, Gastens AM, Volk HA, Loscher W: Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res. 69(1), 1-14 (2006).
15. van Vliet EA, Redeker S, Aronica E, Edelbroek PM, Gorter JA: Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 46(10), 1569-1580 (2005).
16. Wen T, Liu YC, Yang HW et al.: Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on p-glycoprotein expression and activity in the rat brain. J. Neurol. Sci. 270(1-2), 99-106 (2008).
17. Lombardo L, Pellitteri R, Balazy M, Cardile V: Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr. Neurovasc. Res. 5(2), 82-92 (2008).
18. Volk Ha, Loscher W: Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of p-glycoprotein compared with rats with drug-responsive seizures. Brain 128(Pt 6), 1358-1368 (2005).
19. Potschka H, Volk HA, Loscher W: Pharmacoresistance and expression of multidrug transporter p-glycoprotein in kindled rats. Neuroreport 15(10), 1657-1661 (2004).
20. van Vliet EA, van Schaik R, Edelbroek PM et al.: Inhibition of the multidrug transporter p-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47(4), 672-680 (2006).
21. Brandt C, Bethmann K, Gastens AM, Loscher W: The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy Neurobiol. Dis. 24(1), 202-211 (2006).
22. van Vliet EA, van Schaik R, Edelbroek PM et al.: Region-specifc overexpression of p-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J. Pharmacol. Exp. Ther. 322(1), 141-147 (2007).
23. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse p-glycoprotein. Neuropharmacology 52(2), 333-346 (2007).
24. Zhang C, Kwan P, Zuo Z, Baum L: In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human p-glycoprotein. Life Sci. 86(23-24), 899-905 (2010).
25. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human p-glycoprotein. Neuropharmacology 55(8), 1364-1375 (2008).
26. Luna-Tortos C, Rambeck B, Jurgens UH, Loscher W: The antiepileptic drug topiramate is a substrate for human p-glycoprotein but not multidrug resistance proteins. Pharm. Res. 26(11), 2464-2470 (2009).
27. Marchi N, Guiso G, Rizzi M et al.: A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5h-dibenzo(b,f) azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 46(10), 1613-1619 (2005).
28. Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D: Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48(3), 505-516 (2007).
29. Baltes S, Fedrowitz M, Tortos Cl, Potschka H, Loscher W: Valproic acid is not a substrate for p-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 320(1), 331-343 (2007).
30. Crowe A, Teoh Yk: Limited p-glycoprotein mediated effux for anti-epileptic drugs. J. Drug Target 14(5), 291-300 (2006).
31. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK: Carbamazepine is not a substrate for p-glycoprotein. Br. J. Clin. Pharmacol. 51(4), 345-349 (2001).
32. Rivers F, O'Brien TJ, Callaghan R: Exploring the possible interaction between anti-epilepsy drugs and multidrug effux pumps; in vitro observations. Eur. J. Pharmacol. 598(1-3), 1-8 (2008).
33. Potschka H, Fedrowitz M, Loscher W: Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther. 306(1), 124-131 (2003).
34. Gibbs JP, Adeyeye MC, Yang Z, Shen DD: Valproic acid uptake by bovine brain microvessel endothelial cells: Role of active effux transport. Epilepsy Res. 58(1), 53-66 (2004).
35. Luna-Tortos C, Fedrowitz M, Loscher W: Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 58(7), 1019-1032 (2010).
36. Ak H, Ay B, Tanriverdi T et al.: Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure 16(6), 493-503 (2007).
37. Aronica E, Gorter JA, Jansen GH et al.: Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 118(2), 417-429 (2003).
38. Aronica E, Gorter JA, Ramkema M et al.: Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45(5), 441-451 (2004).
39. Dombrowski SM, Desai SY, Marroni M et al.: Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42(12), 1501-1506 (2001).
40. Kubota H, Ishihara H, Langmann T et al.: Distribution and functional activity of p-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res. 68(3), 213-228 (2006).
41. Lazarowski A, Lubieniecki F, Camarero S et al.: Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr. Neurol. 30(2), 102-106 (2004).
42. Aronica E, Gorter JA, Redeker S et al.: Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46(6), 849-857 (2005).
43. Sisodiya SM, Heffernan J, Squier MV: Over-expression of p-glycoprotein in malformations of cortical development. Neuroreport 10(16), 3437-3441 (1999).
44. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M: Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125(Pt 1), 22-31 (2002).
45. Kannan P, John C, Zoghbi SS et al.: Imaging the function of p-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther. 86(4), 368-377 (2009).
46. Ong B, Bergin P, Heffernan T, Stuckey S: Transient seizure-related MRI abnormalities. J. Neuroimaging 19(4), 301-310 (2009).
47. Langer O, Bauer M, Hammers A et al.: Pharmacoresistance in epilepsy: a pilot pet study with the p-glycoprotein substrate r-[(11) c]verapamil. Epilepsia 48(9), 1774-1784 (2007).
48. Bartmann H, Fuest C, la Fougere et al.: Imaging of P-glycoprotein- mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilpesia 51(9), 1780-1790 (2010).
49. Kwan P, Li HM, Al-Jufairi E et al.: Association between temporal lobe p-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol. Dis. 39(2), 192-197 (2010).
50. Summers MA, Moore JL, Mcauley JW: Use of verapamil as a potential p-glycoprotein inhibitor in a patient with refractory epilepsy Ann. Pharmacother. 38(10), 1631-1634 (2004).
51. Iannetti P, Spalice A, Parisi P: Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46(6), 967-969 (2005).
52. Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F: Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 85(1), 89-95 (2009).
53. Löscher W, Klotz U, Zimprich F, Schmidt D: The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 1(1), 1-23 (2008).
54. Kasperaviciute D, Sisodiya SM: Epilepsy pharmacogenetics. Pharmacogenomics 10(5), 817-836 (2009).
55. Sisodiya SM, Marini C: Genetics of antiepileptic drug resistance. Curr. Opin. Neurol. 22(2), 150-156 (2009).
56. Cascorbi I: ABC transporters in drug-refractory epilepsy: limited clinical signifcance of pharmacogenetics? Clin. Pharmacol. Ther. 87(1), 15-18 (2010).
57. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
58. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (p-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004).
59. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specifcity Science 315(5811), 525-528 (2007).
60. Siddiqui A, Kerb R, Weale ME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl. J. Med. 348(15), 1442-1448 (2003).
61. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y: Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-ana lysis. Epilepsia 50(4), 898-903 (2009).
62. Haerian BS, Roslan H, Raymond AA et al.: ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-ana lysis. Seizure 19(6), 339-346 (2010).
63. Sanchez MB, Herranz JL, Leno C et al.: Genetic factors associated with drug-resistance of epilepsy: relevance of stratifcation by patient age and aetiology of epilepsy. Seizure 19(2), 93-101 (2010).
64. Seo T, Ishitsu T, Ueda N et al.: ABCB1 polymorphisms infuence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7(4), 551-561 (2006).
65. Ebid AH, Ahmed MM, Mohammed SA: Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther. Drug Monit. 29(3), 305-312 (2007).
66. Basic S, Hajnsek S, Bozina N et al.: The infuence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy Seizure 17(6), 524-530 (2008).
67. Ozgon GO, Bebek N, Gul G, Cine N: Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur. Neurol. 59(1-2), 67-70 (2008).
68. Kim DW, Lee SK, Chu K et al.: Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy Epilepsy Res. 84(1), 86-90 (2009).
69. Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K: ABCC2 haplotype is not associated with drug-resistant epilepsy J. Pharm. Pharmacol. 60(5), 631-635 (2008).
70. Ufer M, Mosyagin I, Muhle H et al.: Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24CT polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics 19(5), 353-362 (2009).
71. Bailey KR, Cheng C: The great debate: genome-wide association studies in pharmacogenetics research, good or bad? Pharmacogenomics 11(3), 305-308 (2010).
72. Potschka H: Targeting regulation of ABC effux transporters in brain diseases: a novel therapeutic approach. Pharmacol. Ther. 125(1), 118-127 (2010).
73. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H: Seizure-induced up-regulation of p-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 73(5), 1444-1453 (2008).
74. Bankstahl JP, Hoffmann K, Bethmann K, Loscher W: Glutamate is critically involved in seizure-induced overexpression of p-glycoprotein in the brain. Neuropharmacology 54(6), 1006-1016 (2008).
75. Zibell G, Unkruer B, Pekcec A et al.: Prevention of seizure-induced up-regulation of endothelial p-glycoprotein by cox-2 inhibition. Neuropharmacology 56(5), 849-855 (2009).
76. Pekcec A, Unkruer B, Schlichtiger J et al.: Targeting prostaglandin E2 EP1 receptors prevents seizure-associated p-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 330(3), 939-947 (2009).
77. van Vliet EA, Zibell G, Pekcec A et al.: Cox-2 inhibition controls p-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 58(2), 404-412 (2010).
78. Schlichtiger J, Pekcec A, Bartmann H et al.: Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br. J. Pharmacol. 160(5), 1062-1071 (2010).
79. Loscher W, Brandt C: High seizure frequency prior to antiepileptic treatment is a predictor of pharmacoresistant epilepsy in a rat model of temporal lobe epilepsy. Epilepsia 51(1), 89-97 (2010).